Drug intelligence / Profile preview

PLD-107

Development stage: Unknown
Lead developer: Pelemed
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Oral

Overview

PLD-107 is an investigational antibody-drug conjugate (ADC) being developed by Pelemed for the treatment of oncology indications, including acute myeloid leukemia (AML) and various solid tumors. The therapeutic candidate is designed to deliver a novel cytotoxic payload directly to malignant cells. As of 2024, the program is in the discovery phase, and specific details regarding the target antigen and the chemical nature of the payload have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on PLD-107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLD-107.

Explore the full profile